Physician profile
Barbara Brooks Rayo
NPI 1285629915
$2,109.94
in general payments reported to CMS, 2019-2025
24 companies · $292 in 2025
The $292 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $72.64 · 2021: $65.87 · 2022: $345 · 2023: $389 · 2024: $682 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $386.50 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $277.89 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $204.61 | 2019-2025 | Bexsero, Penmenvy |
| Supernus Pharmaceuticals, INC. | $195.09 | 2022-2024 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $169.12 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Kaleo, INC. | $121.76 | 2019-2024 | Auvi-Q |
| Cranial Technologies, INC | $109.67 | 2019-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $90.27 | 2021-2022 | |
| Pfizer INC. | $88.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $63.91 | 2024 | |
| Ironshore Pharmaceuticals INC. | $54.60 | 2024 | |
| Sanofi Pasteur INC. | $50.95 | 2023-2024 | |
| Tris Pharma INC | $46.64 | 2019-2024 | Dyanavel Xr |
| Verrica Pharmaceuticals INC. | $36.37 | 2024 | Ycanth |
| Collegium Pharmaceutical, INC. | $30.87 | 2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $29.95 | 2020-2025 | Relexxii |
| Alk-Abello, INC | $29.70 | 2025 | Neffy |
| Seqirus USA INC | $22.08 | 2024 | Flucelvax |
| Rhodes Pharmaceuticals L.P. | $19.68 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.37 | 2024 | Strensiq |
| Nestle Healthcare Nutrition INC. | $17.26 | 2021 | |
| Avion Pharmaceuticals | $16.09 | 2024 | Methylphenidate Hydrochloride |
| Phadia US INC. | $15.84 | 2022 | |
| Dermira, INC. | $14.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Rayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.